2,654,944 Shares in Savara Inc (NASDAQ:SVRA) Acquired by Rosalind Advisors Inc.

Rosalind Advisors Inc. bought a new position in shares of Savara Inc (NASDAQ:SVRA) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,654,944 shares of the company’s stock, valued at approximately $8,151,000. Savara accounts for 4.0% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 9th biggest position. Rosalind Advisors Inc. owned about 1.55% of Savara at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after buying an additional 1,608,522 shares during the period. Vestal Point Capital LP boosted its holdings in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after acquiring an additional 1,600,000 shares during the period. Jennison Associates LLC grew its position in shares of Savara by 17.5% in the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after purchasing an additional 1,001,296 shares during the last quarter. State Street Corp increased its stake in shares of Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after purchasing an additional 560,242 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after purchasing an additional 264,825 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $2.82 on Friday. The firm has a market capitalization of $483.97 million, a PE ratio of -6.56 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.34. The business’s 50 day moving average is $2.73 and its 200-day moving average is $3.32.

Analyst Ratings Changes

SVRA has been the topic of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Savara currently has an average rating of “Moderate Buy” and an average target price of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.